Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years

  • Authors:
    • Katsumi Mizutani
    • Shoushichi Takeuchi
    • Yasuo Ohashi
    • Michiaki Yakushiji
    • Haruo Nishimura
    • Takeshi Takahashi
    • Toshihiro Maruhashi
    • Kuniaki Ueda
    • Kiichiro Noda
    • You Watanabe
    • Takashi Kawana
    • Yoshiteru Terashima
    • Kazunori Ochiai
    • Shigenori Goto
    • Fumimaro Takaku
    • Kazuo Motoyoshi
  • View Affiliations

  • Published online on: January 1, 2003     https://doi.org/10.3892/or.10.1.127
  • Pages: 127-131
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We performed a randomized double blind study between 1992 and 1995 in which 214 patients with FIGO stage I to III ovarian cancers received administration of 106 units (low dose group) or 8x106 units (high dose group) of macrophage colony-stimulating factor (M-CSF) after cyclophosphamide/adriamycin/cisplatin (CAP) therapy. The period required to finish a set of intensive chemotherapy, which was the primary endpoint, was significantly shortened (p=0.0004), and the incidence of febrile neutropenia significantly decreased (p=0.04). In this study, we followed the patients for a prolonged period. The patients were divided into two groups: patients with complete tumor excision and those with incomplete excision, then the relapse rate and survival rate 5 years after initiation of the clinical study were compared. The relapse rate tended to be lower in the high dose group than in the low dose group in patients with no residual tumor (p=0.0750). However, there was no difference in the relapse rate between the two dose groups in patients with residual tumor. Although there were no significant differences in the survival rate between the high and low dose groups in patients with or without residual tumor, the survival rate in mucinous adenocarcinoma patients with no residual tumor was 64.3% in the low dose group (n=14) and 92.3% in the high dose group (n=14), showing a significantly higher rate (p=0.0436), and the survival rate tended to be higher in the high dose group in patients with serous adenocarcinoma (p=0.0786). Furthermore, in patients aged 40 years or younger with no residual tumor, the survival rates were 73.9 and 100% in the low and high dose groups, respectively, showing a significantly higher rate in the high dose group (p=0.0310). Our results suggest that administration of M-CSF can improve the long-term prognosis of ovarian cancer patients with no residual tumor, but further prospective randomized trials with a primary endpoint of relapse-preventing effect are needed.

Related Articles

Journal Cover

January-February 2003
Volume 10 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mizutani K, Takeuchi S, Ohashi Y, Yakushiji M, Nishimura H, Takahashi T, Maruhashi T, Ueda K, Noda K, Watanabe Y, Watanabe Y, et al: Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years. Oncol Rep 10: 127-131, 2003
APA
Mizutani, K., Takeuchi, S., Ohashi, Y., Yakushiji, M., Nishimura, H., Takahashi, T. ... Motoyoshi, K. (2003). Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years. Oncology Reports, 10, 127-131. https://doi.org/10.3892/or.10.1.127
MLA
Mizutani, K., Takeuchi, S., Ohashi, Y., Yakushiji, M., Nishimura, H., Takahashi, T., Maruhashi, T., Ueda, K., Noda, K., Watanabe, Y., Kawana, T., Terashima, Y., Ochiai, K., Goto, S., Takaku, F., Motoyoshi, K."Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years". Oncology Reports 10.1 (2003): 127-131.
Chicago
Mizutani, K., Takeuchi, S., Ohashi, Y., Yakushiji, M., Nishimura, H., Takahashi, T., Maruhashi, T., Ueda, K., Noda, K., Watanabe, Y., Kawana, T., Terashima, Y., Ochiai, K., Goto, S., Takaku, F., Motoyoshi, K."Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years". Oncology Reports 10, no. 1 (2003): 127-131. https://doi.org/10.3892/or.10.1.127